Scandinavian ChemoTech Starts 2025 Strong with Q1 Order Intake Exceeding USD 230,000

Scandinavian ChemoTech’s Animal Care continues its momentum, achieving an order intake exceeding USD 230,000 (2.3 MSEK) in Q1 2025 which makes it the best quarter so far in regards of sales. This reinforces the steady growth in revenue observed in previous quarters, signaling a positive long-term trend toward profitability.

A key factor behind this success is the increasing recognition of the clinical and financial benefits of TSE treatments. Customer satisfaction remains a cornerstone of our growth, with clients expressing appreciation for both the effectiveness of our technology and the high level of service we provide.

“To start the year with such a strong first quarter is truly encouraging and sets a positive tone for the months ahead,” says Ann Ohlsson, Head of Finance at Scandinavian ChemoTech and VQ Animal Care. “Even with this solid performance, we see our pipeline expanding—not only in terms of business opportunities but also in the speed at which they materialize. Consistently increasing our revenues quarter by quarter strengthens our confidence in our forecasts and long-term potential.”

With this strong start to 2025 and an accelerating demand for our innovative veterinary solutions, Animal Care is well-positioned for continued success. The company remains focused on sustainable growth, bringing the group closer to its first profitable quarter sooner than anticipated.

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 01-04-2025 09:15 CET.